Crossmark

Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial

Crossref DOI link: https://doi.org/10.1186/s12902-023-01442-y

Published Online: 2023-09-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Panigrahi, Antarmayee

Mohanty, Susant
License Information

Text and Data Mining valid from 2023-09-07

Version of Record valid from 2023-09-07
More Information

Article History

Received: 22 November 2022

Accepted: 24 August 2023

First Online: 7 September 2023

Declarations

:

: No individual’s data requring consent is presented in this manuscript.

: Informed consent was given by all participants in this study. The work described was carried out by The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. This study (approval no. SOA/IDS/IRB/2021−10) was approved by the Institutional Ethical Committee (IEC), IMS & SUM Hospital, Siksha ’O’ Anusandhan University, K−8 Kalinga Nagar. Bhubaneswar, Odisha−75003 (on May 17, 2021). The study protocol was registered at ExternalRef removed (CTRI/2021/12/038751, December 20, 2021).

: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Document is current

Any future updates will be listed below